2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Insulin Receptor

Insulin Receptor

Insulin Receptor

Related Products

PDF 0.56 MB

Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.

The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P11237
    Enicepatide
    		Agonist
    Enicepatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research.
    Enicepatide
  • HY-15656S
    Ceritinib-d7
    		Inhibitor 98.00%
    Ceritinib (LDK378)-d7 is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
    Ceritinib-d<sub>7</sub>
  • HY-P10302
    GLP-1R/GIPR agonist-1
    		Agonist
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
    GLP-1R/GIPR agonist-1
  • HY-P3584
    (Pro3) GIP, human
    		Agonist 99.79%
    (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with Ki/ Kd values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes.
    (Pro3) GIP, human
  • HY-P3255
    DA-JC4
    		Agonist
    DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.
    DA-JC4
  • HY-P5431
    Insulin receptor (1142-1153), pTyr1150
    		99.43%
    Insulin receptor (1142-1153), pTyr1150 is a biological active peptide. (Peptide used as insulin receptor tyrosine kinase substrate.)
    Insulin receptor (1142-1153), pTyr1150
  • HY-P2093A
    S961 TFA
    		Antagonist
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
    S961 TFA
  • HY-P2080C
    GIP (1-30)-Myr
    		Agonist
    GIP (1-30)-Myr is the Myr-modified GIP (1-30), which is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) dose-dependently promotes insulin secretion over the range 10-9-10-6 M.
    GIP (1-30)-Myr
  • HY-112819
    Insulin levels modulator
    		Modulator 98.38%
    Insulin levels modulator (Example 49) is an orally active insulin secretagogue. Insulin levels modulator can be used for the research of type 2 diabetes and type 2 diabetes-related disorders.
    Insulin levels modulator
  • HY-P11274
    Zenagamtide
    		Agonist
    Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
    Zenagamtide
  • HY-50866B
    NVP-AEW541 dihydrochloride
    		Inhibitor
    NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity.
    NVP-AEW541 dihydrochloride
  • HY-123547
    TLK19781
    		Activator
    TLK19781 is a non-peptide small molecule insulin receptor activator that increases the content of insulin-stimulated GLUT4 on the cell membrane and enhances the activity of insulin-stimulated glucose transport in cell and animal models of insulin resistance.
    TLK19781
  • HY-P4062
    Insulin peglispro
    Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins.
    Insulin peglispro
  • HY-P3580
    Acetyl Gastric Inhibitory Peptide (human)
    Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.
    Acetyl Gastric Inhibitory Peptide (human)
  • HY-P11270
    Relsipatide
    		Agonist
    Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research.
    Relsipatide
  • HY-P10305
    Visepegenatide
    		Activator
    PB-119 is a PEGylated Exenatide. PB-119 decreases glycemic levels by improving beta-cell function and insulin resistance. PB-119 can be used for research of type 2 diabetes.
    Visepegenatide
  • HY-E70832
    IRR Recombinant Human Active Protein Kinase
    IRR is a member of the insulin receptor (IR) family. IRR activation by alkali is determined by its N-terminal extracellular region. IRR Recombinant Human Active Protein Kinase is a recombinant IRR protein that can be used to study IRR-related functions.
    IRR Recombinant Human Active Protein Kinase
  • HY-N12338
    (+)-Licarin
    		Activator
    (+)-Licarin (Compound 7) is a compound derived from Ocotea macrophylla Kunth. leaves octanoid neolignans.
    (+)-Licarin
  • HY-153503
    ALK-IN-24
    		Inhibitor
    ALK-IN-24 is an orally active ALK inhibitor with an IC50 value of 1.7 nM. ALK-IN-24 also inhibits insulin receptor kinase with an IC50 value of 6 nM. ALK-IN-24 suppresses the proliferation of lung adenocarcinoma cells. ALK-IN-24 inhibits ALK-driven tumor growth in xenograft mouse models. ALK-IN-24 can be used in research related to non-small cell lung cancer.
    ALK-IN-24
  • HY-120401
    Glybuzole
    		Inhibitor
    Glybuzole (Desaglybuzole) is an orally active hypoglycaemic agent that has antidiabetic effect.
    Glybuzole
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity